Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The study aimed to validate previously discovered plasma biomarkers associated with AD, using a design based on imaging measures as surrogate for disease severity and assess their prognostic value in predicting conversion to dementia. METHODS: Three multicenter cohorts of cognitively healthy elderly, mild cognitive impairment (MCI), and AD participants with standardized clinical assessments and structural neuroimaging measures were used. Twenty-six candidate proteins were quantified in 1148 subjects using multiplex (xMAP) assays. RESULTS: Sixteen proteins correlated with disease severity and cognitive decline. Strongest associations were in the MCI group with a panel of 10 proteins predicting progression to AD (accuracy 87%, sensitivity 85%, and specificity 88%). CONCLUSIONS: We have identified 10 plasma proteins strongly associated with disease severity and disease progression. Such markers may be useful for patient selection for clinical trials and assessment of patients with predisease subjective memory complaints.

Original publication




Journal article


Alzheimers Dement

Publication Date





799 - 807.e2


Alzheimer's disease, Biomarker, Mild cognitive impairment, Pathology, Plasma, Prediction and magnetic resonance imaging, Aged, Aged, 80 and over, Apolipoproteins E, Blood Proteins, Cognitive Dysfunction, Cohort Studies, Dementia, Disease Progression, Female, Humans, Immunoassay, Magnetic Resonance Imaging, Male, Mental Status Schedule, Predictive Value of Tests, Prodromal Symptoms, ROC Curve, Statistics as Topic